• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

区域间慢性心力衰竭治疗指南依从性的差异。

Regional Disparities in Adherence to Guidelines for the Treatment of Chronic Heart Failure.

机构信息

Department of Internal Medicine, Niigata Prefectural Tokamachi Hospital, Japan.

Department of Internal Medicine, Uonuma City Koide Hospital, Japan.

出版信息

Intern Med. 2021;60(4):525-532. doi: 10.2169/internalmedicine.4660-20. Epub 2021 Feb 15.

DOI:10.2169/internalmedicine.4660-20
PMID:33583932
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7946489/
Abstract

Objective The incidence of chronic heart failure (CHF) is likely to keep increasing in Japan as the population ages, placing increased burdens on medical facilities, particularly on the limited numbers of rural hospitals. We explored the appropriateness of CHF treatment in rural areas in Japan. Methods We compared rates of adherence to therapeutic guidelines for CHF between residents with a left ventricular ejection fraction <35% living in urban areas (n = 207) and those in rural areas (n = 180). Treatments included pharmacological [beta-blockers, angiotensin-converting enzyme inhibitors (ACEi)/angiotensin II receptor blocker (ARB), mineralocorticoid receptor antagonist (MRA) and anticoagulants for atrial fibrillation] and non-pharmacological [implantable cardioverter defibrillator (ICD)/cardiac resynchronization therapy (CRT), cardiac rehabilitation and HF education] approaches. Patients This study included 387 patients with CHF, prior myocardial infarction or cardiomyopathy, and a left ventricular ejection fraction (LVEF) <35% as determined by echocardiography. Results The respective rates of treatments administered in urban and rural areas were as follows: beta-blockers, 91.3% vs. 61.7% (p<0.05); ACEi/ARB, 86.5% vs. 68.3% (p<0.05); MRA, 74.4% vs. 59.4% (p<0.01); anticoagulants, 100% vs. 86.5%, (p<0.05); ICD/CRT, 45.4% vs. 5.0% (p<0.05); cardiac rehabilitation, 32.4% vs. 13.3% (p<0.05) and HF education, 33.3% vs. 32.8% (p=0.75). Conclusion Regional disparities in treatment for CHF persist, even in Japan. Improvements in the use of guideline-directed treatment in rural areas might improve the outcomes for CHF patients.

摘要

目的

随着人口老龄化,日本慢性心力衰竭(CHF)的发病率可能会继续上升,这给医疗设施,尤其是农村医院带来了更大的负担。我们探讨了日本农村地区 CHF 治疗的适宜性。

方法

我们比较了左心室射血分数(LVEF)<35%的居住在城市(n=207)和农村(n=180)地区的 CHF 患者对治疗指南的依从性。治疗包括药物治疗[β受体阻滞剂、血管紧张素转换酶抑制剂(ACEi)/血管紧张素 II 受体阻滞剂(ARB)、盐皮质激素受体拮抗剂(MRA)和心房颤动的抗凝剂]和非药物治疗[植入式心脏复律除颤器(ICD)/心脏再同步治疗(CRT)、心脏康复和心力衰竭教育]。

患者

这项研究包括 387 名 CHF、既往心肌梗死或心肌病患者,且超声心动图检查 LVEF<35%。

结果

城市和农村地区治疗的比例分别为:β受体阻滞剂,91.3%比 61.7%(p<0.05);ACEi/ARB,86.5%比 68.3%(p<0.05);MRA,74.4%比 59.4%(p<0.01);抗凝剂,100%比 86.5%(p<0.05);ICD/CRT,45.4%比 5.0%(p<0.05);心脏康复,32.4%比 13.3%(p<0.05);心力衰竭教育,33.3%比 32.8%(p=0.75)。

结论

即使在日本,CHF 治疗的区域差异仍然存在。改善农村地区指南指导治疗的使用可能会改善 CHF 患者的结局。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6cb8/7946489/ab09d1f70ac9/1349-7235-60-0525-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6cb8/7946489/a75234a919a5/1349-7235-60-0525-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6cb8/7946489/ab09d1f70ac9/1349-7235-60-0525-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6cb8/7946489/a75234a919a5/1349-7235-60-0525-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6cb8/7946489/ab09d1f70ac9/1349-7235-60-0525-g002.jpg

相似文献

1
Regional Disparities in Adherence to Guidelines for the Treatment of Chronic Heart Failure.区域间慢性心力衰竭治疗指南依从性的差异。
Intern Med. 2021;60(4):525-532. doi: 10.2169/internalmedicine.4660-20. Epub 2021 Feb 15.
2
Nurse-coordinated collaborative disease management improves the quality of guideline-recommended heart failure therapy, patient-reported outcomes, and left ventricular remodelling.护士协调合作的疾病管理可改善指南推荐的心力衰竭治疗、患者报告的结局和左心室重构的质量。
Eur J Heart Fail. 2015 Apr;17(4):442-52. doi: 10.1002/ejhf.252. Epub 2015 Mar 2.
3
Guideline-Directed Medical Therapy Before and After Primary Prevention Implantable Cardioverter Defibrillator Implantation in New Zealand (ANZACS-QI 66).新西兰初级预防植入式心脏除颤器植入前后指南导向的药物治疗(ANZACS-QI 66)。
Heart Lung Circ. 2022 Nov;31(11):1531-1538. doi: 10.1016/j.hlc.2022.06.691. Epub 2022 Aug 20.
4
Efficacy of Pharmacologic and Cardiac Implantable Electronic Device Therapies in Patients With Heart Failure and Reduced Ejection Fraction: A Systematic Review and Network Meta-Analysis.心力衰竭和射血分数降低患者的药物和心脏植入电子设备治疗效果:系统评价和网络荟萃分析。
Circ Arrhythm Electrophysiol. 2019 Jun;12(6):e006951. doi: 10.1161/CIRCEP.118.006951. Epub 2019 Jun 4.
5
Effect of Prescribing Patterns of Renin-Angiotensin System Blockers and Beta-Blockers on Prognosis of Heart Failure.肾素-血管紧张素系统阻滞剂和β受体阻滞剂的开具模式对心力衰竭预后的影响。
Adv Ther. 2020 Sep;37(9):3839-3849. doi: 10.1007/s12325-020-01443-6. Epub 2020 Jul 16.
6
Discharge treatment with angiotensin-converting enzyme inhibitor/angiotensin receptor blocker after a heart failure hospitalisation is associated with a better prognosis irrespective of left ventricular ejection fraction.心力衰竭住院后使用血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂进行出院治疗与更好的预后相关,而与左心室射血分数无关。
Intern Med J. 2019 Dec;49(12):1505-1513. doi: 10.1111/imj.14289.
7
Left ventricular ejection fraction and absence of ACE inhibitor/angiotensin II receptor blocker predicts appropriate defibrillator therapy in the primary prevention population.左心室射血分数以及未使用血管紧张素转换酶抑制剂/血管紧张素II受体阻滞剂可预测一级预防人群中恰当的除颤器治疗。
Pacing Clin Electrophysiol. 2010 Jun 1;33(6):696-704. doi: 10.1111/j.1540-8159.2009.02669.x. Epub 2010 Jan 5.
8
Initiation, Continuation, or Withdrawal of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers and Outcomes in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction.射血分数降低的心力衰竭住院患者中血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂的起始、持续使用或撤药与预后
J Am Heart Assoc. 2017 Feb 11;6(2):e004675. doi: 10.1161/JAHA.116.004675.
9
Effect of Optimization of Medical Treatment on Long-Term Survival of Patients With Heart Failure After Implantable Cardioverter Defibrillator and Cardiac Resynchronization Device Implantation (from the French National EGB Database).优化医疗对植入式心脏复律除颤器和心脏再同步化装置植入术后心力衰竭患者长期生存的影响(来自法国国家EGB数据库)
Am J Cardiol. 2018 Mar 15;121(6):725-730. doi: 10.1016/j.amjcard.2017.12.013. Epub 2018 Jan 3.
10
Long-term changes of renal function in relation to ace inhibitor/angiotensin receptor blocker dosing in patients with heart failure and chronic kidney disease.心力衰竭和慢性肾脏病患者肾功能与血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂剂量的长期变化
Am Heart J. 2016 Aug;178:28-36. doi: 10.1016/j.ahj.2016.03.024. Epub 2016 Apr 30.

引用本文的文献

1
Rural and urban disparities in access and quality of healthcare in the Japanese healthcare system: a scoping review.日本医疗体系中医疗服务可及性与质量的城乡差异:一项范围综述
BMC Health Serv Res. 2025 May 9;25(1):667. doi: 10.1186/s12913-025-12848-w.
2
Association of a Transitional Heart Failure Management Program With Readmission and End-of-Life Care in Rural Japan.日本农村地区过渡性心力衰竭管理项目与再入院及临终关怀的关联
Circ Rep. 2024 Apr 20;6(5):168-177. doi: 10.1253/circrep.CR-24-0030. eCollection 2024 May 10.

本文引用的文献

1
Clinical characteristics and prognostic factors in elderly patients with chronic heart failure -A report from the CHART-2 study.老年慢性心力衰竭患者的临床特征及预后因素——CHART-2研究报告
Int J Cardiol Heart Vasc. 2020 Mar 20;27:100497. doi: 10.1016/j.ijcha.2020.100497. eCollection 2020 Apr.
2
Clinical Characteristics of Heart Failure from Case Reports Presented at the Regional Meeting of the Japanese Society of Internal Medicine.在日本内科医学会地区会议上发表的病例报告中的心衰临床特征
Intern Med. 2019 Aug 1;58(15):2145-2150. doi: 10.2169/internalmedicine.2583-18. Epub 2019 Jun 7.
3
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.
特发性甲状腺素运载蛋白淀粉样变心肌病患者的塔法米迪治疗。
N Engl J Med. 2018 Sep 13;379(11):1007-1016. doi: 10.1056/NEJMoa1805689. Epub 2018 Aug 27.
4
Medical Therapy for Heart Failure With Reduced Ejection Fraction: The CHAMP-HF Registry.射血分数降低的心力衰竭的药物治疗:CHAMP-HF 注册研究。
J Am Coll Cardiol. 2018 Jul 24;72(4):351-366. doi: 10.1016/j.jacc.2018.04.070.
5
Biomarker-Guided Versus Guideline-Based Treatment of Patients With Heart Failure: Results From BIOSTAT-CHF.基于生物标志物与基于指南的心力衰竭患者治疗:BIOSTAT-CHF 研究结果
J Am Coll Cardiol. 2018 Jan 30;71(4):386-398. doi: 10.1016/j.jacc.2017.11.041.
6
Heart Failure With Mid-Range (Borderline) Ejection Fraction: Clinical Implications and Future Directions.心力衰竭伴中间范围(边缘)射血分数:临床意义与未来方向。
JACC Heart Fail. 2017 Nov;5(11):763-771. doi: 10.1016/j.jchf.2017.06.013. Epub 2017 Oct 11.
7
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America.2017年美国心脏病学会/美国心脏协会/美国心力衰竭学会对2013年美国心脏病学会基金会/美国心脏协会心力衰竭管理指南的重点更新:美国心脏病学会/美国心脏协会临床实践指南特别工作组及美国心力衰竭学会的报告
Circulation. 2017 Aug 8;136(6):e137-e161. doi: 10.1161/CIR.0000000000000509. Epub 2017 Apr 28.
8
From breathless to failure: symptom onset and diagnostic meaning in patients with heart failure-a qualitative study.从气喘吁吁到心力衰竭:心力衰竭患者的症状发作及诊断意义——一项定性研究
BMJ Open. 2017 Mar 10;7(3):e013648. doi: 10.1136/bmjopen-2016-013648.
9
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.2016欧洲心脏病学会急性和慢性心力衰竭诊断与治疗指南:欧洲心脏病学会(ESC)急性和慢性心力衰竭诊断与治疗工作组编写,欧洲心脏病学会心力衰竭协会(HFA)提供特别贡献。
Eur Heart J. 2016 Jul 14;37(27):2129-2200. doi: 10.1093/eurheartj/ehw128. Epub 2016 May 20.
10
Implant-based multiparameter telemonitoring of patients with heart failure (IN-TIME): a randomised controlled trial.基于植入物的心力衰竭患者多参数远程监测(IN-TIME):一项随机对照试验。
Lancet. 2014 Aug 16;384(9943):583-590. doi: 10.1016/S0140-6736(14)61176-4.